xanomeline has been researched along with Cognitive Dysfunction in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allen, LA; Baker, E; Brannan, SK; Miller, AC; Paul, SM; Sauder, C | 1 |
| Bryant, ZK; Conn, PJ; Foster, DJ | 1 |
1 review(s) available for xanomeline and Cognitive Dysfunction
| Article | Year |
|---|---|
Targeting muscarinic receptors to treat schizophrenia.
Topics: Animals; Antipsychotic Agents; Clozapine; Cognitive Dysfunction; Humans; Muscarinic Agonists; Pyridines; Receptors, Muscarinic; Schizophrenia; Thiadiazoles | 2021 |
1 trial(s) available for xanomeline and Cognitive Dysfunction
| Article | Year |
|---|---|
Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study.
Topics: Cognitive Dysfunction; Humans; Pyridines; Quaternary Ammonium Compounds; Schizophrenia; Thiadiazoles | 2022 |